scispace - formally typeset
T

Thomas Foltynie

Researcher at UCL Institute of Neurology

Publications -  381
Citations -  26959

Thomas Foltynie is an academic researcher from UCL Institute of Neurology. The author has contributed to research in topics: Deep brain stimulation & Parkinson's disease. The author has an hindex of 80, co-authored 352 publications receiving 21023 citations. Previous affiliations of Thomas Foltynie include University College London & University of Kent.

Papers
More filters
Journal ArticleDOI

Tau and α-synuclein in susceptibility to, and dementia in, Parkinson's disease

TL;DR: The genetic basis of susceptibility to and cognitive heterogeneity of Parkinson's disease is investigated and it is found that the former is linked to higher levels of cognitive impairment and the latter to decreased mobility.
Journal ArticleDOI

Long-term Clinical Outcome of Fetal Cell Transplantation for Parkinson Disease: Two Case Reports

TL;DR: The results from these 2 cases indicate that dopaminergic cell transplantation can offer very long-term symptomatic relief in patients with Parkinson disease and provide proof-of-concept support for future clinical trials using fetal or stem cell therapies.
Journal ArticleDOI

MRI-guided STN DBS in Parkinson's disease without microelectrode recording: efficacy and safety

TL;DR: It is confirmed that image-guided STN DBS without microelectrode recording can lead to substantial improvements in motor disability of well-selected PD patients with accompanying improvements in quality of life and most importantly, with very low morbidity.
Journal ArticleDOI

Parkinson's disease, insulin resistance and novel agents of neuroprotection

TL;DR: In this article, convergence evidence identifying that peroxisome proliferator activated receptor gamma coactivator 1-α, a key regulator of enzymes involved in mitochondrial respiration and insulin resistance, is potentially pivotal in the pathogenesis of neurodegeneration in Parkinson's disease.
Journal ArticleDOI

The heterogeneity of idiopathic Parkinson's disease.

TL;DR: Evidence suggests that sub-groups based on age of onset, motor presentation, or subsequent motor phenotype may have some use in predicting disease progression, however, further clinico-pathological studies are required to evaluate pathological heterogeneity within these groups.